Correspondence 0001683168-23-003817 from Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: June 1, 2023 · CIK: 0001402328 · Accession: 0001683168-23-003817
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272197
Letter
Sunshine Biopharma, Inc.
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
June 1, 2023
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma, Inc.
Registration Statement on Form S-3
Filed May 25, 2023
File No. 333-272197
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sunshine Biopharma, Inc. hereby respectfully requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time, June 5, 2023, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Sunshine Biopharma, Inc.
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
June 1, 2023
Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Re: Sunshine Biopharma, Inc.
Registration Statement on Form S-3
Filed May 25, 2023
File No. 333-272197
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated
under the Securities Act of 1933, as amended, Sunshine Biopharma, Inc. hereby respectfully requests acceleration of the effectiveness
of the above-referenced Registration Statement so that such Registration Statement will become effective as of 4:30 p.m. Eastern Time,
June 5, 2023, or as soon as practicable thereafter.
Very truly yours,
Sunshine Biopharma, Inc.
By:
/s/ Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chief Executive Officer